BioNTech and Pfizer look for the vaccine to rake in sales of around $26 billion this year. BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come.
RICHMOND, Va., July 20, 2021--Owens & Minor will Report Second Quarter Financial Results on Tuesday, August 3, 2021
RICHMOND, Va., June 30, 2021--Press release announcing pilot Electric Vehicle program with Penske.